Potential delays in regulatory approvals for key pipeline products, including subcutaneous formulations of LEQEMBI, were noted as risks to growth projections. Biogen demonstrated solid progress in ...

Biogen Inc (NASDAQ:BIIB) has successfully reduced operating expenses, freeing up resources for growth investments, resulting in improved cash flow. Revenue from new product launches in 2024 more ...